News
West Africa Begins First Clinical Trials For Lassa Fever Vaccine
A biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, INOVIO, on Tuesday announced the first participant was given a shot in Phase 1B clinical trial for INO-4500, its DNA vaccine candidate for Lassa fever, in Ghana.
The Phase 1B clinical trial (LSV-002), ongoing at the Noguchi Memorial Institute for Medical Research in Accra, Ghana, is the first vaccine clinical trial for Lassa fever to be conducted in West Africa, where the infection is endemic. INO-4500 was also the first vaccine candidate for Lassa fever to enter human trials.
INOVIO is advancing INO-4500 with full funding from the Coalition for Epidemic Preparedness Innovations (CEPI), a global partnership that leverages funding from public, private, philanthropic and civil society organizations to support research projects to develop vaccines against emerging infectious diseases. INOVIO previously received a $56 million grant from CEPI in 2018, under which the company is developing vaccine candidates for Lassa fever and Middle East Respiratory Syndrome (MERS). INOVIO and CEPI are committed to making a vaccine available as soon as possible for emergency use as a stockpile product post-Phase 2 testing.
President and Chief Executive Officer (CEO) of INOVIO, Dr. J. Joseph Kim, said, “We have already observed that INO-4500 vaccination generates robust antibody and T cell immune responses in Phase 1 clinical trial conducted in the U.S., and this continued advancement of INO-4500 into Phase 1B trial is another important step in a fight against Lassa fever. This trial also represents a significant advancement within INOVIO’s infectious disease portfolio and further validates the company’s DNA medicines platform and proprietary CELLECTRA® delivery device.”
Kim added, “This is the same device being used to deliver our DNA vaccine candidate, INO-4800, in the Phase 2 segment of our INNOVATE Phase 2/3 COVID-19 trial. We are grateful to CEPI for the continued support and confidence in our vaccine programs – and we look forward to advancing INO-4500 as a vaccine candidate against Lassa fever.”
- Top Stories15 hours ago
Mohbad’s toxicology result ready…what you need to know
- News15 hours ago
FG to review fresh price hike of DStv, GOtv packages
- Top Stories15 hours ago
Witness Reveals How Ex-HoS, Oyo-Ita, Others Diverted ₦3 Billion To Private Companies
- Entertainment15 hours ago
Israeli supermodel, Bar Refaeli accuses Bella Hadid of spreading fake news with photo of ‘starving Gaza child’
- News16 hours ago
Black Market Dollar (USD) To Naira (NGN) Exchange Rate Today 26th April 2024
- Top Stories58 mins ago
BREAKING: TINUBU APPOINTS NIGERIA’S RENOWNED BANKER, JIM OVIA AS CHAIRMAN OF NIGERIAN EDUCATION LOAN FUND
- Sports15 hours ago
Osimhen reveals how he was pushed to become like Drogba
- Business and Brands15 hours ago
Glo, MTN, Airtel, Others Move To Raise Tariff